Literature DB >> 9870443

Lessons from 494 permanent accesses in 348 haemodialysis patients older than 65 years of age: 29 years of experience.

L Berardinelli1, A Vegeto.   

Abstract

Currently, patients older than 65 years of age constitute more than 42% of all new enrolments for dialytic treatment in the USA and Italy. Most of these patients are treated by in-centre haemodialysis (HD), with problems connected to vascular access. Personal experience of 494 new vascular accesses in 348 'difficult' HD-patients older than 65 years over 29 years showed the best results from 221 elbow fistulas in comparison with 32 forearm fistulas (78% vs 57.2% at 3 years; P < 0.05). Among various vascular substitutes, the homologous saphenous vein (HSV) graft, alone or mixed (MX) gave the best secondary patency in comparison with other organic-semiorganic (OSO) or synthetic graft (SYN) angioaccesses with values of 59.4% for HSV, 66.3% for MX, 21.9% for OSO, and 38.6% for SYN grafts, respectively at 3 years.

Entities:  

Mesh:

Year:  1998        PMID: 9870443     DOI: 10.1093/ndt/13.suppl_7.73

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  3 in total

Review 1.  Vascular access in elderly patients with end-stage renal disease.

Authors:  Nikolaos Bessias; Kosmas I Paraskevas; Effie Tziviskou; Vassilios Andrikopoulos
Journal:  Int Urol Nephrol       Date:  2008-09-16       Impact factor: 2.370

Review 2.  Optimal hemodialysis vascular access in the elderly patient.

Authors:  Louise M Moist; Charmaine E Lok; Tushar J Vachharajani; Wang Xi; Ahmed AlJaishi; Kevan R Polkinghorne; Miguel Vazquez; Timmy C Lee
Journal:  Semin Dial       Date:  2012 Nov-Dec       Impact factor: 3.455

3.  Outcomes of Primary Arteriovenous Fistula for Hemodialysis in Elderly Patients (>65 Years) with End Stage Renal Disease: A Study on Indian Population.

Authors:  P Gaur; A Srivastava; S K Sureka; R Kapoor; M S Ansari; U P Singh
Journal:  Indian J Nephrol       Date:  2019 Nov-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.